2023-505923-30-00招募中2 期
Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response to therapy - ICARUS-BREAST01
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 99
- 试验地点
- 11
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Bureau projet Promotion- DRC
Scientific
Institut Gustave Roussy
研究点 (11)
Loading locations...
相似试验
尚未招募
Unknown
Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 FusioKCT0009451Samsung Medical Center30
进行中（未招募）
2 期
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung CancerNon-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorNCT04619004Daiichi Sankyo277
招募中
2 期
Phase 2 study of Trastuzumab Deruxtecan in the neoadjuvant treatment for patients with HER2 positive gastric and gastroesophageal junction adenocarcinomaHER2 positive gastric and gastroesophageal junction adenocarcinomaJPRN-jRCT2031210313Shitara Kohei37
招募中
1 期
Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low Breast Cancer Patients Presenting with Newly Diagnosed or Progressing Brain Metastases. (The TUXEDO-4 Study)HER2-low breast cancer presenting with newly diagnosed or progressing brain metastases with or without type II leptomeningeal disease.CTIS2023-506702-39-00Medica Scientia Innovation Research S.L.27
招募中
2 期
Phase II Study of daTopotamab-derUXtecan (Dato-DXd; DS-1026a) in triple-negative brEast cancer patients with newly Diagnosed or prOgressing brain metastases2024-518819-19-00Medical University Of Vienna20